Loading
A phase 2/3 trial of Margetuximab, Retifanlimab and Trastuzumab in HER2-positive gastric cancer, run by MacroGenics, completed.
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer is a phase 2/3 interventional study registered as NCT04082364 by MacroGenics, with 82 participants recorded, started 2019-09-30 and reaching its primary completion in 2024-01-15. Interventions recorded: margetuximab, Retifanlimab, Tebotelimab, Trastuzumab, Chemotherapy. Conditions recorded: Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer.
Linked to the drug Margetuximab because the registry names it among its interventions and HER2-positive gastric cancer among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
82 enrolled.
95% CI 37.2 to 66.7; Figures from the ClinicalTrials.gov results section (first posted 2025-04-22), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) for Non-microsatellite Instability-high (Non-MSI-H) Participants (Cohort A) Using Investigator-assessed Radiology Reviewsprimary | Chemotherapy-free Arm | 48 | 52.1% | - | - | link |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MacroGenics, Margetuximab, Trastuzumab and the tag pipeline.
Shares Margetuximab, Trastuzumab and the tag pipeline.
Shares Retifanlimab and the tag pipeline.
Shares HER2-positive gastric cancer, Trastuzumab and the tag pipeline.
Shares Retifanlimab and the tag pipeline.
Shares HER2-positive gastric cancer and the tag pipeline.
Shares MacroGenics and the tag pipeline.
Shares HER2-positive gastric cancer, Trastuzumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/